CVC Catalyst, the mid‑market arm of private‑equity group CVC, has agreed to buy a majority stake in WillowWood, a leading U.S. prosthetics maker. Founded in 1907, the company pioneered the gel liner that cushions the interface between a residual limb and a prosthesis. The deal signals a push to scale a century‑old precision‑engineering business for better mobility solutions across different patient groups globally.

Since 2018, co‑CEOs Mahesh Mansukhani and Daniel Rubin have expanded WillowWood’s portfolio to include nearly 1,000 SKUs and added in‑house manufacturing in Ohio and Mesa, Arizona. The team has launched 18 new product launches since 2021, driving growth in prosthetic feet, knees and custom fabrication. CVC plans to accelerate research and pursue bolt‑on acquisitions to expand capabilities and market share.

CVC will use its global healthcare platform to build a direct commercial presence in Europe, where the opportunity is deemed substantial. The transaction follows a similar playbook seen in investments like Rayner and Therakos, pairing research acceleration with international expansion. The deal, terms undisclosed, is slated to close in Q3 2026 pending regulatory approval, positioning WillowWood for accelerated growth and value for shareholders.